Background: Upregulation of kallikreins (KLKs) including KLK5 has been reported in atopic dermatitis (AD). KLK5 has biological functions that include degrading desmosomal proteins and inducing proinflammatory cytokine secretion through protease-activated receptor 2 (PAR2). However, due to the complex interactions between various cells in AD inflamed skin, it is difficult to dissect the precise and multiple roles of upregulated KLK5 in AD skin. Objective: We investigated the effect of upregulated KLK5 on the expression of epidermal-related proteins and cytokines in keratinocytes and on skin architecture. Methods: Lesional and nonlesional AD skin biopsies were collected for analysis of morphology and protein expression. The relationship between KLK5 and barrier-related molecules was investigated using an ex vivo dermatitis skin model with transient KLK5 expression and a cell model with persistent KLK5 expression. The influence of upregulated KLK5 on epidermal morphology was investigated using an in vivo skin graft model. Results: Upregulation of KLK5 and abnormal expression of desmoglein 1 (DSG1) and filaggrin, but not PAR2 were identified in AD skin. PAR2 was increased in response to transient upregulation of KLK5, whereas persistently upregulated KLK5 did not show this effect. Persistently upregulated KLK5 degraded DSG1 and stimulated secretion of IL-8, IL-10, and thymic stromal lymphopoietin independent of PAR2 activity. With control of higher KLK5 activity by the inhibitor sunflower trypsin inhibitor G, restoration of DSG1 expression and a reduction in AD-related cytokine IL-8, thymic
Tissue kallikreins (KLKs) are a family of 15 (chymo)trypsinlike serine proteases that function through proteolytic cascades in the skin. Eight KLKs are expressed in the skin with KLK5 being 1 of the 3 most important, the others being KLK7 and KLK14. 1 KLK5 is produced as an inactive precursor from keratinocytes and activated by matriptase and KLK14, 2, 3 but it can also undergo self-activation. It is able to activate other KLKs, therefore, KLK5 has been considered to be the initiator of KLK activation cascades within the skin. 4 KLK5 is expressed in the outmost layers of the epidermis, and the importance of its biological function in the epidermal barrier was initially discovered through studies on Netherton syndrome (NS), a rare severe autosomal recessive skin disorder caused by mutations in the SPINK5 gene. 4, 5 In NS, SPINK5 mutations cause loss of function of its encoded protein LEKTI, a multidomain serine protease inhibitor, leading to elevated activity of KLK5. This results in cleavage of intercellular adhesion protein desmoglein 1 (DSG1), causing excessive desquamation of corneocytes and leading to a severely defective skin barrier, which is a major cause of early neonatal death in NS. 6 In addition to its involvement in DSG1 degradation, KLK5 is able to activate protease activated receptor 2 (PAR2), a subfamily of G proteincoupled receptors, and trigger expression of proinflammatory cytokines such as IL-8. 7, 8 KLK5 is also involved in the innate immune system within the skin by cleaving the cathelicidin precursor cationic antimicrobial protein 18 at its c-terminus to produce 37 amino acid peptide LL-37, a major antimicrobial peptide with broad-spectrum antimicrobial activity. 9 Upregulation of KLKs including KLK5 has been reported in many chronic inflammatory skin diseases including atopic dermatitis (AD). 10, 11 AD is a multifactorial disease caused by complex interactions between genetic and environmental factors, with evidence that irritants (such as those contained in soaps) can further damage the skin barrier and exacerbate the inflammation in AD patients. 12 In the past decade, significant progress has been made in the area of molecular genetics with identification of several genes linked to AD including SPINK5, KLK7, and FLG. [13] [14] [15] These findings have led to the proposition that an impaired epidermal barrier is the primary event, allowing percutaneous allergen penetration and causing an enhanced T H 2-skewed immune response. 16 The induced inflammatory response further compromises barrier function, resulting in abnormal expression, activity, and assembly of skin barrier-related proteins, enzymes, and lipids. Aberrant upregulation of KLK5 in AD skin has been reported, 10, 11 and increased KLK5 may play a key role in the pathogenesis of the dysfunctional skin. However, due to the complex interactions between various cells in AD inflamed skin, it is difficult to dissect the exact role of upregulated KLK5 in AD skin.
In this study, we confirmed upregulation of KLK5 and abnormal expression of KLK5 downstream molecules DSG1 and filaggrin (FLG), but not PAR2 in AD skin. We also identified significantly increased KLK5 and PAR2 expressions in an ex vivo dermatitis model, but not in the cell model with persistent overexpression of KLK5, illustrating different responses of PAR2 to transient or persistent KLK5 stimulation. We also demonstrated that increased IL-8, IL-10, and thymic stromal lymphopoietin (TSLP) in keratinocytes with persistently expressed KLK5 was independent of PAR2 activity, and that inhibition of KLK5 activity with the serine protease inhibitor sunflower trypsin inhibitor G (SFTI-G) reduced cytokine production and normalized DSG1 protein expression. Furthermore, persistent KLK5 overexpression alters keratinocyte behaviour in vivo, resulting in epidermal acanthosis similar to that observed in AD skin, indicating a key role for KLK5 in AD pathology.
METHODS

Skin biopsies and hematoxylin and eosin staining
Skin biopsies were taken from nonlesional and lesional skin from 5 AD patients. Five age-matched healthy donors were also obtained. The study was approved by Institute of Child Health/Great Ormond Street Hospital Research Ethics Committee (LREC number 05/Q0508/106). Skin samples were formalin-fixed paraffin-embedded, and hematoxylin and eosin staining was performed on 6-mm thickness paraffin skin sections using standard histochemistry techniques.
Immunostaining and protein quantification
Immunofluorescence and immunohistochemistry staining were carried out on frozen or paraffin-embedded tissue sections using 1 of the following: a purified anti-KLK5 mouse polyclonal antibody in 1:500 dilutions (Novus Biologicals, Abingdon, United Kingdom [UK]), an anti-DSG1 mouse monoclonal antibody recognizing N-terminal extracellular domain (clone P124) in 1:100 dilutions (2B Scientific Ltd, Upper Heyford, UK), an anti-FLG monoclonal antibody in 1:100 dilutions (Leica Biosystems, Newcastle, UK), an anti-involucrin mouse monoclonal antibody in 1:1000 (Sigma, Dorset, UK), or an anti keratin 10 mouse monoclonal antibody (clone number LHP2, a gift from Royal London Hospital, UK). Molecular Probes secondary antibodies conjugated with florescence dye were obtained from Life Technologies (Paisley, UK). The detection of immunohistochemistry used biotinylated secondary antibodies and diaminobenzidinetetrahydrochloride substrate kit for peroxidase (Vector Laboratories, Peterborough, UK). The staining procedures were described by Di et al, 17 and negative controls were performed in each staining with the secondary antibody alone.
The quantification of protein expression and activity in the epidermis was performed based on the staining intensity using software Image-Pro Plus v6.0 (Media Cybernetics, Cambridge, UK). Briefly images of 3 nonoverlapped but adjacent regions in each section were recorded and saved digitally. The epidermis in each image was then highlighted as an area of interest (AOI) and the defined positive staining threshold was applied to the AOIs. The optical counts of positive staining within AOIs were automatically counted based on the defined threshold and the expression or activity in each AOI was calculated as mean staining intensity/area.
Primary keratinocyte and keratinocyte cell line culture
Primary keratinocytes and fibroblasts were isolated from skin biopsies by incubation with 0.25% trypsin-EDTA (Life Technologies) 3 hours for keratinocytes and Serva 50 U/mL collagenase NB6 (Universal Biologicals, Cambridge, UK) 2 hours for fibroblasts. Isolated primary keratinocytes were then cocultured with lethally irradiated 3T3 mouse fibroblasts and grown in keratinocyte culture media. The media contained equal amounts of Dulbecco modified Eagle medium (DMEM) and DMEM/Ham F12 (Life Technologies) supplemented with 10% FCS (Labtech, East Sussex, UK), 100 IU/mL of penicillin and 100 mg/mL of streptomycin (Life Technologies). Human keratinocyte growth supplement was then added to the media at final concentrations of 10 ng/mL of epidermal growth factor (Bio-Rad AbD Serotec, Oxford, UK), 0.4 mg/mL of hydrocortisone, 5 mg/mL of transferrin, 5 mg/mL of insulin, 2 3 10 211 mol/L of liothyronine and 1 3 10 210 mol/L of cholera toxin (Sigma, Dorset, UK). Ntert, 18 a keratinocyte cell line was cultured in the same keratinocyte media. Fibroblasts were cultured in DMEM supplemented with 10% FCS, 100 IU/mL of penicillin, and 100 mg/mL of streptomycin.
Ex vivo dermatitis model and immunofluorescent staining
Skin from female breast tissue, obtained with informed consent and ethical approval (Southampton and South West Hampshire Research Ethics Committee, LREC 07/Q1704/59) following mastectomy was used as an ex vivo dermatitis model. The skin, which was surplus to histopathology requirement, was placed in ice-cold PBS immediately following removal and stored on ice for a maximum of 2 hours, then placed into a 60-mm petri dish and the epidermal surface carefully blotted dry. Rubber O-rings with a diameter of 8 mm were sealed on to the skin using soft paraffin wax to create wells; care was taken to ensure that paraffin wax was applied only to the area where the O-ring made contact with the skin in order to avoid altering the permeability of the skin or the protease activity within the epidermis. To prevent the skin from drying out during the incubation period, the remaining space within the petri dish was filled with DMEM, containing 10% FCS, at a depth of approximately 2 mm, ensuring no medium touched the epidermal surface of the skin. Irritant substances and appropriate vehicle controls were applied carefully to separate wells (50 mL solution each) and the skin incubated at 378C with 5% CO 2 for the required length of time. Following incubation, the entire irritant and vehicle control solutions were aspirated off the epidermis and 6-mm punch biopsies were taken from the treated sites of the skin sample (without removing the rubber O-rings) using sterile biopsy punches. A fresh biopsy punch was used for each treatment to avoid cross-contamination, and the biopsy was removed from within the rubber O-ring using forceps to ensure only treated skin was extracted. The biopsied tissue was placed in a 1.5 mL Eppendorf tube (Hamburg, Germany) and snap frozen in liquid nitrogen. Samples were stored at 2808C until further investigations.
Following removal of skin biopsies from 2808C storage and embedding in Tissue-Tek optimal cutting temperature medium (Sakura Finetek, Thatchem, UK), 8-mm tissue sections were cut on a cryostat, allowed to dry onto poly-Llysine coated glass slides, then fixed for 10 minutes in ice cold acetone at 2208C. Slides were washed with TRIS-buffered saline (TBS), blocked for 30 minutes with blocking buffer, followed by incubation with primary antibody in TBS overnight at 48C. Slides were washed for 3 times for 5 minutes each time in TBS, subsequently incubated with secondary antibody for 1 hour in the dark, then washed in TBS for 3 times for 5 minutes each time, and, where necessary, counterstained by incubation with 49-6-diamidino-2-phenylindole, dihydrochloride for 10 minutes, followed by a final wash of for 3 times for 5 minutes each time in TBS. Coverslips were attached using Mowiol and the samples then visualized by fluorescence microscopy (Axioskop 2 MOT; Zeiss, Oberkochen, Germany). Slides were magnified 1003 and 4003 and images were digitally recorded (Axiocam; Zeiss). Slides stained in the absence of primary antibody were used to set the exposure levels to reduce background staining. Images were analyzed using ImageJ v1.46 software (National Institutes of Health, Bethesda, Md), with 10 vertical regions of interest from outer to inner surface of the epidermis selected from 1 field of view from 3 consecutive sections for each sample, and the contribution from each layer along this measurement was recorded. The 10 measured regions of interest were normalized to 100% and the mean pixel intensity was obtained for every 5% of the depth (ie, from outer to inner surface) of the epidermis. The minimum average pixel intensity for a 5% section in the PBS sample was set at 1, and all other readings for the sample set were calculated relative to this value.
Construction of lentiviral vectors and transduction of keratinocytes
Human KLK5 cDNA was cloned into the pCCL lentiviral vector containing upstream spleen focus-forming virus promoter and downstream enhanced green fluorescent protein (eGFP) reporter gene linked to KLK5 via an internal ribosomal entry sequence from the endomyocarditis virus. The vector encoding eGFP alone was used as negative control. Lentiviruses were produced by cotransfecting 293T cells. Infectious lentiviruses were harvested 48 and 72 hours posttransfection, and the culture supernatants were concentrated by ultracentrifugation. The lentivirus concentration was titrated by viral copy number using quantitative PCR and flow cytometry and the titers of eGFP viral vector and KLK5/eGFP viral vector were 8 3 10 8 and 4 3 10 8 transduction unit/mL, respectively. Human primary keratinocytes and cell line Ntert were transduced by 1 round of exposure to eGFP or KLK5/eGFP vectors at a multiplicity of infection of 10. Transduced cells were subcultured for further experiments.
Intracellular calcium mobilization assay
Measurement of intracellular calcium mobilization was performed using FluoForte Calcium Assay kit (Enzo Life Sciences, Exeter, UK). Mobilization of intracellular calcium was detected using a fluorogenic calcium-binding dye. Keratinocytes were plated in 96-well plates at the density of 1 3 10 4 cells per well. After 24 hours, the growth medium was removed and 100 mL of dyeloading solution was added. The cells were further incubated with the dyeloading solution for 45 minutes at 378C and then 15 minutes at room temperature. The cells were then inoculated with 100 mmol/L of PAR2-activating peptide SLIGKV-NH 2 , (Bachem, Cambridge Bioscience, Cambridge, UK), and intracellular calcium signal was recorded via real-time monitoring of fluorescence intensity at excitation of 530 nm and emission of 570 nm using the microplate reader FLUOstar OPTIMA (BMG, Lutterworth, UK). Intracellular calcium mobilization was calculated as changes of fluorescence intensity in relative fluorescence units and the mobilization curves were generated by relative fluorescence unit values plotted against the time.
Western blotting
Cells were suspended in a cooled lysis buffer composed of 50 mmol/L TRISHCl pH 8.0, 150 mmol/L NaCl, 5 mmol/L EDTA, cocktail protease inhibitors, and 1 mmol/L phenylmethylsulfonyl fluoride. Samples were incubated for 15 minutes at 48C and then were centrifuged at 12,000 revolutions/minute for 15 minutes. The total protein concentration in the supernatant of lysed sample was determined by Bio-Rad protein assay Kit. Samples were further diluted 5 times in 0.5 mmol/L TRIS-HCl pH 6.8 sample buffer containing 100 mmol/L dithiothreitol, 10% SDS, 30% glycerol, and 0.001% bromophenol blue. Equal amounts of total protein were loaded in SDS-PAGE. After electrophoresis, proteins were transferred to polyvinylidene fluoride membranes and incubated with primary antibody overnight. The following day, membranes were incubated with secondary antibody conjugated with horseradish peroxidase (Sigma, Poole, UK), and signals were detected using the ECL Prime system (GE Healthcare, Bucks, UK). Ponceau red (Sigma-Aldrich, Poole, UK) staining was used as loading control for culture supernatants.
In situ zymography and casein gel zymography
In situ zymography assay using casein-derived substrate measured the total protease activity in the skin. Briefly, the frozen skin sections were rinsed with PBS containing 0.1% Triton X-100 (Sigma-Aldrich) and incubated at 378C with 10 mg/mL casein conjugated with BODIPY TR-X (Life Technologies) in the buffer containing 10 mmol/L TRIS-HCl, pH 7.8 in a humid chamber for 2 hours. The fluorescent intensity was detected under a fluorescence microscope and quantified using Image-Pro.
Casein gel zymography was used for cells that were cultured in keratinocyte culture media without FCS for 48 hours. The culture media were then collected and concentrated using Amicon centrifugal filter devices (Millipore, Watford, UK). Samples were redissolved in nonreducing Novex TRIS-glycine SDS sample buffer (Life Technologies) and separated on 12% polyacrylamide gels copolymerized with casein substrate (Life Technologies). After electrophoresis, the gels were soaked in renaturing buffer containing 50 mmol/L TRIS, pH 8 and 2.5% Triton X-100 for 1 hour. The gels were then incubated in developing buffer containing 50 mmol/L TRIS, pH 8 (Life Technologies) at 378C overnight. Casein degrading activity was visualized when the gels were stained with 1% Coomassie Brilliant blue (Sigma-Aldrich).
Human cytokine antibody array
The cytokines in culture media collected from the different cell lines were assessed using the Human Cytokine Antibody Array Panel A kit (R&D Systems, Oxfordshire, UK) according to the manufactory's instruction. A total of 36 cytokines were measured and the intensities of the blots were quantified by densitometry. As each reference or target protein was blotted in duplicate, mean pixel density from duplicate blots was calculated and normalized by reference blots.
RT-PCR for IL-8
Following RNA extraction using the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany), a second genomic DNA elimination step was employed to prevent genomic DNA contamination, and cDNA was then synthesized using the RT 2 first strand kit (SABiosciences, Hilden, Germany). Quantitative PCR was performed in duplicate wells for each time point using a 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, Calif) and the data collected using SDS 2.4 software (Applied Biosystems). The PCR protocol consisted of an initial cDNA denaturation at 958C for 10 minutes, followed by 35 cycles of denaturation at 958C for 15 seconds and annealing and data collection at 608C for 60 seconds. DCT values were calculated using the cycle threshold value for the housekeeping gene 26S, and analysis of fold change in gene regulation was performed using automated Microsoft Excel analysis tools from SABiosciences.
ELISA
Cells were seeded in 24-well plates and cultured until confluence, then cultured in serum-free media for 48 hours before culture media were collected and concentrated using Amicon centrifugal filter devices (Millipore). The total protein concentration was quantified using Bio-Rad protein assay kit. The level of IL-8 was measured using IL-8 ELISA kit (BD Biosciences, Oxford, UK).
TSLP and IL-10 were quantified using ELISA kits from eBioscience (Hatfield, UK). All sample reads were normalized to the total protein concentration.
Bioengineered skin sheet and grafting onto immunodeficient mice
The methods of generating bioengineered skin sheet and grafting to mice were as described by Di et al. 19 Briefly, primary human keratinocytes were seeded on the top of a fibrin matrix populated with primary human fibroblasts. After keratinocytes reached confluence, the bioengineered skin constructs were grafted onto the dorsum of 6-week-old female immunodeficient mice (NMRI strain, Charles River, Canterbury, UK). Eight weeks after grafting, skin samples from grafts were taken postmortem and formalin-fixed and paraffin-embedded or optimal cutting temperature medium-embedded. Hematoxylin and eosin staining and immunostaining for KLK5, FLG, and DSG1 and zymography were performed on these tissues.
RESULTS
Increased expression and activity of KLK5 in AD skin
Skin biopsies taken from lesional and nonlesional skin in 5 children with AD were examined for epidermal morphology and KLK5 expression. Five age-matched normal donor skin biopsies were used as controls. Compared with normal skin, AD lesional skin exhibited epidermal changes including acanthosis, spongiosis, parakeratosis, and elongated rete ridges. Nonlesional skin also showed histopathological characteristics consistent with the disease, but far less prominent than those observed in lesional skin (Fig 1, A, a-c) . The expression of KLK5, as detected by immunostaining, was localized in the cornified layer in normal skin, whereas in AD skin, especially in the lesional skin, KLK5 was present in the granular layer and upper stratum spinosum with high staining intensity (Fig 1, A, d -f, and Fig E1 in this article' s Online Repository at www.jacionline.org). Quantification of KLK5 based on mean optical staining intensity/area further demonstrated significant increased expression of KLK5 in both lesional and nonlesional AD skin, compared with the normal skin (P < .05) (Fig 1, B) . As DSG1 is the proteolytic substrate of KLK5, and FLG can be degraded by elastase 2, which is a serine protease activated by KLK5 in the skin, 20 DSG1 and FLG expressions were also examined by immunostaining. Both FLG and DSG1 expression were significantly reduced in lesional skin of AD (P <.05) (Fig 1, A, g-l, and B) . The protease activity in the skin were further examined by in situ staining, and results showed a similar location and staining pattern to KLK5 expression with more diffuse and enhanced fluorescence intensity in the AD skin (Fig 1, A, m-o, and B, and Fig E2 in this article' s Online Repository at www.jacionline.org). Although the caseinolytic serine protease assay detects total protease activity, as KLK5 is a major serine protease in the skin 2 and the protease activity closely matched the extent and distribution of KLK5 protein expression, it is likely that KLK5 is a significant contributor to the increased activity of serine protease observed in the AD skin.
Transient upregulation of KLK5 stimulated PAR2, but persistently activated KLK5 desensitized PAR2
The expression of the KLK5 targeted molecule PAR2 was further examined in the donor skin (n 5 5) and AD nonlesional and lesional skin by immunostaining. No significant changes in PAR2 expression were noted in lesional, nonlesional AD skin, and normal donor skin (P > .05) (Fig 1, A, p-r, and B) , although there was a fluctuation of PAR2 expression level among individuals. This result suggests that upregulated KLK5 does not modify PAR2 in AD skin. Considering that the upregulation of KLK5 was likely to be chronic and persistent in AD skin, we speculated that the response of PAR2 to KLK5 might differ between AD skin and skin with transient KLK5 upregulation. To determine this, the influence of transiently increased KLK5 on PAR2 was tested using an ex vivo irritant dermatological model in which irritants were applied onto normal skin cultured in vitro. Following the application of croton oil or SDS or acetone for 30 minutes on the ex vivo skin model, increased epidermal expression of KLK5 and PAR2 were detected in the epidermis (Fig 2, A) . Quantification using image analysis confirmed significantly higher expression of both KLK5 and PAR2 across all layers of the epidermis (Fig 2, B-E) .
The effect of persistently increased KLK5 on PAR2 was tested in the keratinocyte cell line Ntert (KLK5-Ntert) or primary keratinocytes (KLK5-pKC) ectopically overexpressing KLK5. Cells transduced with eGFP vector alone were used as control (GFP-Ntert or GFP-pKC). The transduction efficiency in both KLK5 transduced cells and GFP transduced cells was nearly 60% as determined by eGFP expression. Overexpression of KLK5 in KLK5-transduced cells and culture media was confirmed by Western blotting (Fig 3, A and C) . The activity of KLK5 was further assessed by zymography. Active KLK5 was detected in the culture media collected from KLK5 transduced cell culture (Fig 3, D) , but not in cell lysates (Fig 3, B) . KLK5 is synthesized as inactive pre-pro-KLK5 (precursor or zymogene), which is then translocated into the endoplasmic reticulum in cells (see review by Debela et al 21 ). Following the removal of the signal peptide (;30 amino acids), the pre-pro-KLK5 becomes pro-KLK5 that is secreted into the extracellular space and subsequently becomes activated on release of its 37 amino acids propeptide from the N-terminus of KLK5. Thus, the KLK5 extracted from the cells would not contain the final activated KLK5, and it is not surprising that there was no positive digested band detected in zymography loaded with cell lysates. In contrast, a digested band was seen in zymography loaded with culture medium from cells overexpressing KLK5/eGFP as a result of the culture medium containing the active form of KLK5. Although a ;70 kDa band was present on both Western blotting and D) and PAR2 (C and E) expression from stratum corneum to basal layer (0%-100% depth, respectively). KLK5 (n 5 9, n 5 7), PAR2 (n 5 7, n 5 6) for 3% croton oil and 5% SDS, respectively. zymography, the intensity of the protein band remained unchanged among cell lysates from untransduced cells, cells transduced with GFP alone, and cells transduced with KLK5/ GFP; therefore, this was considered to represent a nonspecific protein, but one having a proteolytic activity on casein-derived substrate.
The durability of KLK5 expression in both KLK5-Ntert and KLK5-pKC was assessed following propagation of transduced cells, and there was no decline in KLK5 expression over this time as determined by eGFP expression, indicating persistent KLK5 expression in the KLK5-cell model (see Fig E3 in this article' s Online Repository at www.jacionline.org). As a previous study showed that PAR2 was mainly expressed in differentiated keratinocytes, the Ntert cell line was checked for differentiation markers keratin 10 and involucrin, and results showed positive expression for both proteins (see Fig E4 in this article' s Online Repository at www.jacionline.org). The activity of PAR2 and a KLK5 downstream target was then examined in untransfected Ntert, GFP-Ntert, and KLK5-Ntert by a PAR2-dependent calcium mobilization assay. Mobilization of calcium was observed in the untransfected keratinocytes after addition of a PAR2 agonist (AP), and similarly following addition of recombinant KLK5 (rKLK5), albeit slightly later than that induced by AP (Fig 4, A) , confirming that KLK5 was able to activate PAR2. In contrast, a decline in calcium mobilization was detected in KLK5-Ntert cells compared with that in GFP-Ntert (Fig 4, B) . Thus, a different PAR2-dependent calcium mobilization response was observed in cells with persistent expression of KLK5 versus cells with transient rKLK5 stimulation.
PAR2, like many other receptors, can be desensitized if continuously or repeatedly exposed to its agonist, 22, 23 and these results suggest that persistent overexpression of KLK5 could desensitize the PAR2 receptor resulting in a lower response of PAR2 to its agonist AP. Because PAR2 desensitization can be reversed by removal of PAR2 activators, we looked at calcium mobilization when KLK5-Ntert cells were treated with the serine protease inhibitor SFTI-G, an analogue derived from the naturally occurring substance sunflower trypsin inhibitor 1. 24 Following treatment with 100 mmol/L SFTI-G overnight, the PAR2-dependent calcium mobilization in KLK5-Ntert cells recovered to levels similar to that in GFP-Ntert and untransfected keratinocytes (Fig 4, C) .
Persistently activated KLK5 induced cytokine expression/secretion despite PAR2 desensitization Activated PAR2 induced proinflammatory cytokine elevation and secretion, including of IL-8, has been reported. 25 In the ex vivo irritant dermatological skin model, increased IL-8 mRNA expression was detected by RT-PCR within 12 hours following exposure to SDS and to a lesser extent at 12 hours following application of croton oil (Fig 5, A) . In the KLK5-pKC cells with persistent KLK5 expression, IL-8 protein, measured by cytokine antibody array, was also increased (Fig 5,  B and C) . In addition, IL-10 was elevated in KLK5-pKC cells (Fig 5, B and C) , but other cytokines including IL-1, IL-4, IL-6, and IFN-g were not (see Table E1 in this article's Online Repository at www.jacionline.org). TSLP, a prominent proinflammatory cytokine in AD skin also showed increased expression in KLK5-pKC cells as measured by ELISA (Fig 5, C) . However, increased IL-10 and TSLP were not detected in cells transiently challenged with rKLK5 (data not shown).
Inhibition of persistent KLK5 activity reversed KLK5 effects on DSG1 and cytokine production
To examine the downstream effects of inhibition of persistently raised KLK5 activity, pKCs transduced with KLK5 (KLK5-pKC) or eGFP (GFP-pKC) were cultured in serum-free media inoculated with 100 mmol/L of serine protease inhibitor SFTI-G for 24 hours. Although the level of secreted KLK5 in culture media, as determined by Western blot, remained elevated in the KLK5-pKC cells 24 hours post-SFTI-G treatment, the expression of full-length DSG1 was restored in treated KLK5-cells compared with untreated cells, whereas there was no significant change in the level of DSG1 in GFP-pKC cells before (-) and after SFTI-G (1) treatment, indicating the suppression of KLK5 activity by SFTI-G in the KLK5 culture (Fig 6, A) . It was noticed that in KLK5-pKC cells, there was no DSG1 detected. The DSG1 antibody used in the study was a monoclonal antibody (clone P124) recognizing the N-terminal extracellular domain of DSG1 and full-length DSG1. Primary keratinocytes were used for untreated as well as treated experiments, and treated cells showed a DSG1 band. Therefore, no DSG1 band in KLK5-pKC cells without SFTI-G treatment was most likely due to DSG1 levels being to too low to be detected and/or the antibody does not recognize the cytoplasm domain of DSG1 alone following the cleavage of the extracellular domain by overexpressed/activated KLK5. Cytokines IL-8, IL-10, and TSLP were also significantly reduced in SFTI-G-treated KLK5-pKC cells, compared with untreated KLK5-pKC cells, and these changes were not observed in treated or untreated GFP cells as confirmed by both cytokine antibody array and ELISA ( Figs 5, B and 6 , B and C, Table E1 ).
Keratinocytes with persistently activated KLK5 exhibit an AD-like epidermal architecture
To examine the influence of persistently upregulated KLK5 activity on epidermal architecture in vivo, primary keratinocytes from the nonlesional skin in a patient with AD (AD-pKC) or primary normal keratinocytes ectopically overexpressing KLK5 (KLK5-pKC) or GFP (GFP-pKC) were cultured in vitro as bioengineered skin and grafted onto immunodeficient mice. Eight weeks post grafting, the skin from the grafted area was harvested. Grafts generated from KLK5-pKC and AD-pKC showed AD-like morphology, with acanthosis, mild parakeratosis, and enlarged intercellular spaces compared with the GFP-pKC graft (Fig 7,  A-C) . Increased expression of KLK5 and protease activity and decreased DSG1 were observed in both KLK5-pKC and AD-pKC grafts compared with GFP-cell graft (Fig 7, D-L) , which were analogous to findings in AD skin. Altered FLG expression was also detected in KLK5-pKC and AD-pKC grafts, and it was more evident in the upper stratum spinosum similar to that seen in the AD skin (Figs 1, A, h and i, and 7 , M-O). As the FLG antibody used for the study only detects FLG produced from human cells, the mouse-human skin boundary was easily visible in the FLG-stained skin, indicating that the keratinocytes within the grafts were of human origin (Fig 7, G-I ). In addition, the mouse-human skin boundary images showed an increased thickness of mouse epidermis (acanthosis) next to the grafts generated by KLK5-pKC and AD-pKC, but not by the GFPpKC, which may have resulted from a paracrine effect of activated KLK5 secreted from these grafts.
DISCUSSION
Upregulated KLK5 together with skin barrier defects in AD have been reported in previous studies, 10, 11, 26 which have shown that both genetic and environmental factors can cause aberrant KLK5 activity. Indeed, as AD shares a number of clinical features with NS, it has been speculated that AD might also share some pathological mechanisms of dysfunctional skin barrier with NS. 27, 28 Genomewide association studies have shown several single nucleotide polymorphisms in SPINK5 associated with AD, in particular Glu420Lys, 28 and functional investigations have further confirmed that Glu420Lys single nucleotide polymorphism alters SPINK5 encoded protein LEKTI proteolytic activation and results in dysregulation of proteases including the KLKs. 29 Environmental factors that disrupt the skin barrier, including irritants and infection, and trigger KLK5 upregulation have also been reported. 30 In this study, we have demonstrated that the irritants croton oil and SDS increase KLK5 and PAR2 expression, but that transient KLK5 expression seems to have different effects on PAR2 expression/activity than that observed with persistent KLK5 expression.
KLK5 activation of PAR2 has been demonstrated previously, 31 and we also showed rKLK5 activated PAR2 in this study using an intracellular calcium mobilization fluorescence assay. The fluorescence peak induced by rKLK5 was, however, delayed 4 to 50 seconds compared with the peak induced by AP. This difference in peak time was likely to be due to the tethered ligand mechanism with regard to maximum rate of PAR2 activation by KLK5. Oikonomopoulou et al 31 have reported that KLK5 activation of PAR2 is a 2-step process involving cleavage and tethered ligand binding to the PAR2 receptor, whereas a 1-step process is involved in the PAR2 agonist directly binding to the receptor.
The signaling pathway of KLK5-PAR2-nuclear factor-kBcytokines has been recognized for more than a decade, 32, 33 but most studies have been carried out in models with transient exposure to exogenous rKLK5.
31
PAR2 can exhibit desensitization due to continuous or repeated stimulation by its agonist, leading to reduced responsiveness. 34 AD is a chronic skin condition, and upregulated KLK5 activity in affected skin is more likely to be persistent than transient. However, the examination of PAR2 activity in skin in situ is technically difficult. Currently, the activity of PAR2 is assessed by intracellular calcium mobilization in live cells following stimulation/inhibition with its agonist/antagonist. Tissues from AD skin or murine AD models are generally fixed/embedded or snap frozen and thus are not suitable for use in the calcium mobilization assay. There is an indirect way to check PAR2 activity by examination of PAR receptor internalization, for example, by tracking GFP-tagged PAR2 fusion protein trafficking 35 or by analyzing the distribution of activated (cytoplasmic) and unactivated (cell membrane) PAR2 receptor, 36 but these also require cell-culture models rather than skin tissue. However, although the desensitization of PAR2 in the skin in situ cannot be measured directly, previous work by Moniaga et al 37 supports our view that PAR2 is desensitized in AD-like skin lesions. In their study, 37 a PAR2 agonist could upregulate TSLP in murine keratinocytes following transient (oneoff) stimulation, but only a marginal increase of TSLP production was noted in the skin of flaky tail mice following repeated topical application of dust mite for 7 weeks; this discrepancy of TSLP production between transient stimulation in cell culture and repeated challenge in mouse skin was probably because the repeated challenge caused PAR2 desensitization, resulting in low PAR2 activity. Related to this, an in vivo study by Briot et al 38 showed that TSLP production was independent of PAR2 activation and that PAR2 was not central to the production of the skin inflammation when there was persistent KLK5 activity. In mice with double knockout of SPINK5 2/2 and PAR2
2/2
and high KLK activity, the deletion of PAR2 in the adult double knockout-grafted skin did not result in the reduction of TSLP and did not suppress the skin inflammation. 38 This result suggests that the inflammatory skin in NS and AD is not solely caused by PAR2 activation.
Based on our observations in the AD skin with persistent KLK5 overexpression and the ex vivo irritant dermatological skin model mimicking a transiently increased KLK, we demonstrated that PAR2 had a higher response to transient KLK5 stimulation, but had a weak response to persistent KLK5 stimulation. Interestingly, despite the low activity of PAR2 in cells overexpressing KLK5, these cells upregulated and secreted proinflammatory and T H 2-polarizing cytokines, including IL-8, IL-10, and TSLP, indicating that persistent KLK5 induced IL-8, IL-10, and TSLP. The exact pathway of persistent KLK5 expression/activity induced IL-8, IL-10, and TSLP secretion in KLK5-pKC remains unclear, and further investigations will be required to elucidate this. The keratinocyte-based nature of our KLK5 overexpressing model, which lacks immune cells, meant that it was not possible to investigate cytokine secretion from immune cells following KLK5 activation, which may explain why our cytokine antibody array data did not show elevation of other cytokines/chemokines reported in AD patients (such as IL-6, IL-4, GM-CSF, IL-1, and TNF-a).
The influence of activated KLK5 on epidermal architecture in the in vivo human-murine chimeric skin graft model, which showed AD-like skin architecture in grafts generated using cells overexpressing KLK5, further indicated that KLK5 plays a key role in this process. Similar observations have also been detected using a transgenic mouse model overexpressing KLK5. 39 Furthermore, as the human-murine chimeric skin graft model was immunodeficient and maintained in specific pathogen-free environment, our results suggest that the AD-like histopathological features and abnormal barrier protein expression in the epidermis generated by AD cells and KLK5-pKC cells were a specific consequence of persistent upregulation of KLK5 in the keratinocytes.
Our study also suggests that increased KLK5 in AD skin should not simply be viewed as a ''biomarker'' in this skin disorder, but as a protease that has significant functional impact in this condition. In AD patients, environmental factors can trigger the cytokine cascade and stimulate a T H 2-skewed inflammatory infiltrate through the initial defective skin barrier, resulting in susceptibility to allergy or ''atopy'' (''outside-inside'' etiologic mechanism). 16, 40 The induced inflammatory response further compromises barrier function, causing keratinocyte damage and inducing upregulation of certain molecules, such as KLK5. The initial damage secondary to increased KLK5 forms a vicious cycle of inflammation-induced barrier impairment in AD (outside-inside-outside). 16 Among the currently known inhibitors of KLKs, [41] [42] [43] the naturally occurring cyclic peptide SFTI has been extensively investigated due to it being amenable to chemical manipulation, which has allowed for the creation of synthetic variants. [44] [45] [46] We used the analogue SFTI-G derived from SFTI 24 to control KLK5 activity and our in vitro results showed a normalized DSG1 expression, depletion of depressed PAR2-dependent calcium mobilization, and reduction of IL-8, IL-10, and TSLP. Thus, reducing KLK5 activity could offer a therapeutic option for the treatment of AD, where control of higher KLK5 activity might help to reverse (at least part of) the AD phenotype in patients with this disorder.
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Key messages
d Persistently upregulated KLK5 induces PAR2-independent IL-8, IL-10, and TSLP secretion, causing abnormal keratinocyte growth and AD-like skin architecture.
d Inhibition of KLK5-mediated effects restored DSG1 expression and decreased AD-related cytokine expression, thus suggesting that KLK5 inhibition may be useful as a potential treatment for AD. 
